Biotime-Nasdaq's best kept secret? Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Biotime-Nasdaq's best kept secret?

BTIM 0.0001000

0.0%

Nov 5 1:26 PM EST

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: Bill Wexler who wrote (904)	5/3/1998 2:05:00 PM
From: Stephen How	Read Replies (1) of 1432

Abbott may get a fair deal out of this. I see that Biotime is also pursuing a pentastarch expander (Pentalyte&reg = pentastarch + electrolytes). I notice that Abbott does not have a generic pentastarch to compete with Dupont's Pentaspan&reg, although they do market a generic hetastarch to compete with Dupont's Hespan&reg. If Abbott gets a pentastarch to sell for the price of the Hextend licensing deal, then it could be a good deal for Abbott. I'll have to check into the full details of the agreement. Steve btim.dyn.ml.org

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next